Predictive value of methicillin-resistant staphylococcus aureus nasal swab in patients with COVID-19 pneumonia and secondary bacterial pneumonia.

Predictive value of methicillin-resistant staphylococcus aureus nasal swab in patients with COVID-19 pneumonia and secondary bacterial pneumonia.

Publication date: Feb 01, 2024

To determine the performance measures of admission methicillin-resistant Staphylococcus aureus (MRSA) nasal swabs for MRSA bacterial pneumonia in patients co-infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The study included patients admitted with SARS-CoV-2-positive nasopharyngeal specimens, MRSA nasal screens, and bacterial cultures to assess secondary MRSA pneumonia. 293 patients and 662 microbiological cultures evaluated. Overall, the specificity (91. 8% [95% CI 88. 6% to 95%]) and negative predictive value (NPV 97. 4% [95% CI 95. 4% – 99. 3%]) of MRSA nasal swabs was high. However, the sensitivity (46. 2%; 95% CI 19. 1% to 73. 3%) and positive predictive value (PPV 20. 7%; 95% CI 59. 5 – 35. 4%) were low. Those patients in the MRSA nasal swab negative group had a shorter median duration of linezolid therapy. SARS-CoV-2 infection doesn’t reduce the specificity or negative predictive value of MRSA nasal swabs for secondary MRSA pneumonia.

Concepts Keywords
Methicillin COVID
Microbiological MRSA nasal swab
Pneumonia Negative predictive value
Staphylococcus Specificity

Semantics

Type Source Name
drug DRUGBANK Meticillin
disease VO Staphylococcus aureus
disease MESH COVID-19
disease MESH pneumonia
disease MESH bacterial pneumonia
disease VO Severe acute respiratory syndrome coronavirus 2
drug DRUGBANK Linezolid
pathway REACTOME SARS-CoV-2 Infection

Original Article

(Visited 1 times, 1 visits today)